Evidence map›Paper›PMID 32808069›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2021

Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models.

Takahiko Imai, Shohei Tsuji, Hirohumi Matsubara, Takuya Ohba, Tomoki Sugiyama, Shinsuke Nakamura, Hideaki Hara, Masamitsu Shimazawa

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Efficacy of desferrioxamine mesylate in intracerebral hematoma: a systemic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Therapeutic potential of iron chelators in retinal vascular diseases.International journal of ophthalmology · 2023
    Review
  16. Article
  17. Neuroinflammation in Friedreich's Ataxia.International journal of molecular sciences · 2022
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Takahiko ImaiMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.
Shohei TsujiMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.
Hirohumi MatsubaraMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.
Takuya OhbaMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.
Tomoki SugiyamaMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.
Shinsuke NakamuraMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.
Hideaki HaraMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.
Masamitsu ShimazawaMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan. shimazawa@gifu-pu.ac.jp.
Gifu Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIntracranial hemorrhage (ICH) is a devastating disease with high mortality and morbidity. After ICH, iron released from the hematoma plays a crucial role in secondary brain injury. Deferasirox (DFR) is a trivalent iron chelator, which was approved to treat iron overload syndrome after transfusion. The aim of the present study was to investigate the protective effects of DFR in both in vitro and in vivo ICH models.

methodsUsing a hemin-induced SH-SY5Y cell damage model, we performed an intracellular bivalent iron (Fe

resultsDFR significantly suppressed the intracellular Fe

conclusionThese findings indicate that DFR might be a useful therapeutic agent for the therapy of ICH.

Indexed as

AnimalsAntioxidantsApoptosisAutophagyBrainCell DeathCell Line, TumorDeferasiroxDisease Models, AnimalHemorrhagic StrokeHumansIronIron Chelating AgentsMaleMiceNeuronsAntioxidantsDeferasiroxIronIron Chelating AgentsNeuroprotective AgentsReactive Oxygen SpeciesDeferasiroxHeminIntracranial hemorrhageIron chelatorNeuronOxidative stress

Identifiers

PMID32808069
OpenAlexW3076801834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.